Skip to main navigation Skip to search Skip to main content

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome - Recall following different chemotherapy agents

  • Yuk Fung Hui
  • , Francis J. Giles
  • , Jorge E. Cortes
  • Department of Cancer Biology

Research output: Contribution to a Journal (Peer & Non Peer)Review articlepeer-review

16 Citations (Scopus)

Abstract

Radiation recall is a phenomenon commonly seen in patients receiving chemotherapy treatment who have previously been exposed to radiation. A phenomenon not clearly described is that of a side effect induced by one chemotherapy agent and later recalled when the patient is given a different chemotherapy regimen. Troxacitabine is an anti-leukemic agent which can be associated with palmar-plantar erythrodysesthesia syndrome (PPES). Here, we report six cases of troxacitabine-induced PPES that was later recalled by various chemotherapy regimens. The recall PPES was mild to moderate and self-limiting in all cases. All of these patients recovered from the recall side effects with minimal medical intervention. We conclude that a recall phenomenon similar to that described after radiotherapy might occur after certain chemotherapy agents. This phenomenon should be considered when evaluating toxicity from chemotherapy, particularly when using new and investigational agents.

Original languageEnglish
Pages (from-to)49-53
Number of pages5
JournalInvestigational New Drugs
Volume20
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Chemotherapy
  • Palmar
  • Plantar
  • Recall
  • Side effects
  • Troxacitabine

Fingerprint

Dive into the research topics of 'Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome - Recall following different chemotherapy agents'. Together they form a unique fingerprint.

Cite this